Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390338 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by Pawel Kalinski.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT00390338 is a Phase 1 study of Melanoma (Skin) that has completed, run by Pawel Kalinski. The registered enrollment target is 22 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00390338, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Pawel Kalinski.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells. Infusing the vaccine directly into the lymphatic system may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of two dendritic cell vaccines in treating patients with stage III or stage IV melanoma.
Conditions Studied
Interventions
- BIOLOGICAL polarized dendritic cells
- BIOLOGICAL non-polarized dendritic cells
Study Locations (2)
Pennsylvania
- UPMC Cancer Center at Magee-Womens Hospital - Pittsburgh
- UPMC Cancer Centers - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390338
The ClinicalTrials.gov registry entry for NCT00390338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (84% lower). The listed sponsor is Pawel Kalinski, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which polarized dendritic cells is the first listed.
NCT00390338 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00390338 about?
NCT00390338 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells. Infusing the vaccine directly into the lymphatic system may cause a stronger immune response and kill more tumor cells. PURPOSE: ...
What is the current status of trial NCT00390338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-10. Estimated completion is 2015-01.
What conditions does trial NCT00390338 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00390338?
The interventions under investigation include: polarized dendritic cells (BIOLOGICAL), non-polarized dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00390338?
This trial is sponsored by Pawel Kalinski, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390338 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.